Evidence‐based guideline for the diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2023)
Abstract
Mycoplasma pneumoniae pneumonia (MPP) is the most common atypical pneumonia among children, with non‐specific clinical manifestations. Despite various laboratory diagnostic methods, the diagnostic criteria remain inconsistent, potentially leading to missed or overdiagnosis. The incidence of severe and refractory cases of MPP is increasing, and there are issues with non‐standard treatment in clinical practice. To standardize the diagnosis and treatment of MPP in Chinese children, the Subspecialty Group of Respiratory, the Society of Pediatrics, Chinese Medical Association, China National Clinical Research Center of Respiratory Diseases and the Editorial Board of Chinese Journal of Pediatrics jointly established a guideline expert group to formulate the “Evidence‐Based Guideline for the Diagnosis and Treatment of Mycoplasma Pneumoniae Pneumonia in Children (2023)” based on both domestic and international research findings.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.